Information  X 
Enter a valid email address

Sunrise Resources (SRES)

  Print      Mail a friend

Thursday 01 November, 2018

Sunrise Resources

Nominated Adviser Status

RNS Number : 0967G
Sunrise Resources Plc
01 November 2018
 

 

SUNRISE RESOURCES PLC

("Sunrise" or the "Company")

1 November 2018

Nominated Adviser Status

The directors of Sunrise Resources are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners Limited ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement nominated adviser by 4 March 2019 the admission of its AIM Securities will be cancelled. 

The Company's board has already initiated talks with a number of parties to appoint a new Nomad and is confident that a suitable replacement will be appointed by the required date. A further announcement will be made in due course.

Further information:

Sunrise Resources plc

Patrick Cheetham, Executive Chairman  

Tel:

+44 (0)1625 838 884

 

 

 

Northland Capital Partners Limited

Nominated Adviser & Joint Broker

Matthew Johnson/Edward Hutton/

Jamie Spotswood (Corporate Finance)

Isabella Pierre (Corporate Broking)

 

Tel:

+44 (0)20 3861 6625

 

SVS Securities Plc

Joint Broker

Tom Curran/Ben Tadd

Tel:

+44 (0)203 700 0093 

Shares in the Company trade on AIM. EPIC: "SRES". Website: www.sunriseresourcesplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUAVVRWAAARAA

a d v e r t i s e m e n t